Answers are grounded in this paper and cite their sources.
CAF-targeted nanodrug delivery improves treatment in colorectal cancer, suggesting new strategies for patient care.
CAF-targeted nanodrug delivery offers a transformative opportunity to address long-standing barriers in CRC therapy. Future advances will depend on the integration of multi-omics CAF subtyping, rational combination regimens, and clinically scalable nanocarriers to translate these strategies into a lasting clinical benefit.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: